Novartis' decision to withdraw chronic migraine biologic AIMOVIG (erenumab) from last week's PBAC meeting will contribute to achieving the goal of a "50 percent reduction in the number of resubmissions to the PBAC". Was this the intent of the PBS process improvements initiative?
Reducing submission 'churn' by getting rid of resubmissions?
November 11, 2019 Latest NewsNews of the Day
Latest Video
New Stories
-
Australia’s life sciences sector emerges as fast growing, globally connected powerhouse
May 21, 2026 - - Latest News -
They used to forecast growth, it was not real and couldn't be used, and it made the program a target for cuts
May 21, 2026 - - Latest News -
New report reveals how AI is now deciding which healthcare brands Australians see online
May 21, 2026 - - Latest News -
Medicine shortages and workforce gaps threaten the sustainability of Australian care
May 21, 2026 - - Latest News -
Sanofi therapy wins Australian registration for non-relapsing secondary progressive MS
May 20, 2026 - - Latest News -
Owen Smith: 'We are ready to negotiate. We are ready to be a genuine partner'
May 19, 2026 - - Latest News -
Australia bets on translational science to turn discovery into global impact
May 19, 2026 - - Latest News
